Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Atossa Therapeutics(ATOS) Newsfilter·2024-03-12 20:30Atossa Therapeutics, Inc.任命Tessa Cigler博士为董事会成员 - Tessa Cigler博士是纽约市Weill Cornell Breast Center的医学肿瘤学家和临床研究员[2] Atossa Therapeutics, Inc.正在开发(Z)-endoxifen的口服制剂 - (Z)-endoxifen是FDA批准的选择性雌激素受体调节剂（SERM）他莫昔芬的最活跃代谢物[3] - Atossa正在开发(Z)-endoxifen的专有口服制剂，无需肝脏代谢即可达到治疗浓度[4]